Working hand in hand to provide innovative diagnostic solutions to those who need it most.

Focusing on the science of HPV, Roche has developed advanced solutions to find disease early and prevent invasive cervical cancer from developing.

Thrombophilia is a predisposition to develop blood clots.

Chlamydia trachomatis (CT) is one of the most common sexually transmitted infections (STIs), but not all testing options are appropriate to manage the spread of disease.

Polymerase chain reaction (PCR), one of the most important scientific advances of the 20th century, is an efficient and cost-effective way to copy or “amplify” small segments of DNA or RNA.

Learn the importance of limiting the impact of the most common non-viral sexually transmitted infection. Advances in testing can help you to slow the spread of this curable parasitic disease.

Learn more about how the Roche diagnostics Zika test is enabling blood screening that helps healthcare authorities respond to challenging medical emergencies

To enable early and accurate detection of WNV, Roche offers the cobas® TaqScreen West Nile Virus Test and cobas® West Nile Virus test for the direct detection of WNV RNA for donor screening and provides broad detection of other related flaviviruses that may cause transfusion-transmitted diseases.

Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care

Roche's CINtec PLUS Cytology, when used as a triage test for high-risk HPV, showed a significantly higher sensitivity in detecting cervical pre-cancers in HPV-positive women compared to Pap cytology.

Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.

Roche is starting a collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for improved patient care.

Roche today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19.

The Open Environment allows software developers to easily integrate their image analysis tools for tumour tissue with Roche uPath enterprise software.

Roche press release: Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy.

cobas® 6800/8800 Systems are included as part of the updated World Health Organization (WHO) policy guidelines on nucleic acid amplification tests (NAATs) to detect tuberculosis (TB) and drug-resistant TB. The new guidance expands the number of rapid molecular tests available to national TB programmes in high-burden countries, enabling multi-partner diagnostic approaches that can benefit patients and communities.